<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2705">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469491</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0041</org_study_id>
    <nct_id>NCT04469491</nct_id>
  </id_info>
  <brief_title>Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study</brief_title>
  <acronym>COV-NI</acronym>
  <official_title>Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 is causing a serious viral pandemic in terms of health and social impact. To date,&#xD;
      no treatment has yet demonstrated its efficacy in treating the infectious disease (COVID-19).&#xD;
      Pulmonary administration of Interferon (IFN) type I is a therapeutic strategy with high&#xD;
      potential,due to higher local concentrations and minimal adverse effects. Type I interferons&#xD;
      (including IFN-α and IFN-β) are antiviral defence cytokines and also have the potential to&#xD;
      negatively modulate IFN Type II and IL-6 dependent cytokine storm, the latter being induced&#xD;
      in the late forms of COVID-19. In vitro, IFN-β were more effective on COVID-19 than IFN-α. In&#xD;
      existing preliminary studies, only patients receiving IFN type I modulators have a decrease&#xD;
      in viral carriage and a rapid reversal. The purpose of this project is to assess in&#xD;
      hospitalized patients with oxygen for COVID 19, the clinical efficacy on oxygen requirements&#xD;
      of the addition of inhaled Interferon type I compared to the control arm .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    In anticipation for Data and Safety Monitoring Board&#xD;
  </why_stopped>
  <start_date type="Actual">September 20, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oxygen requirement score at day 0</measure>
    <time_frame>day 0</time_frame>
    <description>oxygen requirement score at day 0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oxygen requirement score at day 15</measure>
    <time_frame>day 15</time_frame>
    <description>oxygen requirement score at day 15</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation oxygen requirement score between day 0 and day15</measure>
    <time_frame>at day 15</time_frame>
    <description>Variation oxygen requirement score between day 0 and day15</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID-19</condition>
  <condition>INTERFERON</condition>
  <condition>NEBULIZATION</condition>
  <arm_group>
    <arm_group_label>Inhaled IFN arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN (Interferon) pulmonary (Inhalation) + routine care (+/- antibiotics; + appropriate O2 support)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aerosol (WFI water and routine care (+/- antibiotics; + appropriate O2 support).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled type I interferon</intervention_name>
    <description>The interventional arm includes inhaled type I interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days), in addition to standard care.</description>
    <arm_group_label>Inhaled IFN arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WFI water nebulization</intervention_name>
    <description>The interventional arm includes a WFI water nebulization comparator.</description>
    <arm_group_label>Control Arm:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Patient with laboratory-confirmed COVID-19 infection as determined by PCR &lt; 96 h (at&#xD;
             initial diagnosis or aggravation phase with persistent carriage &lt;96 h)&#xD;
&#xD;
          -  Inpatients with COVID-19 of any duration, requiring oxygen therapy (mask or mechanical&#xD;
             ventilation).&#xD;
&#xD;
          -  Social security coverage&#xD;
&#xD;
          -  Signed informed consent (by patient or their legally authorized representative)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to natural or recombinant interferon-ß&#xD;
&#xD;
          -  Hypersensitivity to human albumin or mannitol&#xD;
&#xD;
          -  Recent suicide attempt&#xD;
&#xD;
          -  Decompensation of liver failure&#xD;
&#xD;
          -  age &lt; 18 years&#xD;
&#xD;
          -  Pregnant or nursing.&#xD;
&#xD;
          -  Patients managed on an outpatient basis (i.e. not initially hospitalized).&#xD;
&#xD;
          -  Parenteral IFN treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe Lanoix, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>INTERFERON</keyword>
  <keyword>NEBULIZATION</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon Type I</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

